加载中
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
收盘时
US$38.45
−US$0.61 · -1.56%
盘后
US$37.94
−US$0.51 · -1.33%
10月12日 19:13 ET
盘中时间采用ET。市场数据可能有所延迟。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日内区间
当前US$38.45
52周区间
当前US$38.45
盘中时间采用ET。市场数据可能有所延迟。
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
日内区间
当前US$38.45
52周区间
当前US$38.45
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 226.6万 USD | — | — | — | — |
| 毛利 | −226.6万 USD | — | — | — | — |
| 研究与开发 | 1.51亿 USD | 1.27亿 USD | 9090.5万 USD | 5403.2万 USD | 3218.9万 USD |
| 销售、一般及管理费用 | 4001.7万 USD | 3186.6万 USD | 2345.2万 USD | 1762.6万 USD | 1102.6万 USD |
| 营业费用 | 1.89亿 USD | 1.59亿 USD | 1.14亿 USD | 7165.8万 USD | 4321.5万 USD |
| 利息收入 | 2361.1万 USD | 2501.9万 USD | 1419.4万 USD | 266.4万 USD | 40.2万 USD |
| 利息支出 | — | — | — | 401.8万 USD | — |
| 折旧和摊销 | 226.6万 USD | 229万 USD | 173.2万 USD | 53.8万 USD | 27.2万 USD |
| 营业利润 | −1.91亿 USD | −1.59亿 USD | −1.14亿 USD | −7165.8万 USD | −4321.5万 USD |
| 净利润 | −1.68亿 USD | −1.34亿 USD | −1亿 USD | −6764万 USD | −4281.3万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$53.10
上涨空间 38.10%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.22亿0.01%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM7307.3万0.09%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF3656.63万0.04%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO2580.14万0.19%139.17亿 USD0.24%US$353.71-0.86%
iShares Biotechnology ETFIBB2477.38万0.23%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Russell 2000 ETFVTWO1717.14万0.09%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA1676.26万0.08%218.24亿 USD0.03%US$32.66-0.40%
iShares U.S. Pharmaceuticals ETFIHE1107.41万0.71%15.52亿 USD0.37%US$100.19+0.10%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAiShares U.S. Pharmaceuticals ETFIHEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
